Bacteriophage compositions for treating clostridium perfringens infections
AssigneeAparon Ltd.
InventorsJoseph Charles Samuel BROWN, Joseph Riziero EDWARDS, Sammy James KAY, Ellen Olivia DENNESS, Christopher Jeremy STANFORD
Life of this patent
Estimating the term…
Abstract
The invention relates to the field of phage therapy. It particularly relates to providing phages, phage-based compositions and methods for treating or preventing bacterial infections, particularly C. perfringens, in animals, including humans, aquaculture and livestock. The invention also relates to uses of the compositions as a feedstuff and as a biological decontaminator in feed and food products for human and animal consumption.
Claims21
A bacteriophage:
- (a) wherein the genome of the bacteriophage has a nucleotide sequence as given in SEQ ID NO:
- 11;
- or
- (b) wherein the genome of the bacteriophage has a nucleotide sequence which has at least 90% (preferably at least 95% or 99%) sequence identity to SEQ ID NO:
- 11
- and wherein the bacteriophage is capable of lysing one or more strains of Clostridium perfringens.
A bacteriophage:
- (a) wherein the genome of the bacteriophage has a nucleotide sequence as given in any one of SEQ ID NOs:
- 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
- or
- (b) wherein the genome of the bacteriophage has a nucleotide sequence which has at least 90% (preferably at least 99%) sequence identity to any one of SEQ ID NOs:
- 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and wherein the bacteriophage is capable of lysing one or more strains of Clostridium perfringens.
A pharmaceutical composition comprising a bacteriophage as claimed in any one of the preceding claims, together with one or more pharmaceutically-acceptable carriers, excipients or diluents.
Dependencies are inferred from the claim text.